TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...

The treatment of bladder cancer could see a major advancement thanks to an innovative drug delivery approach. This targeted ...

June 10, 2004 (New Orleans) — Results of a phase III trial of front-line therapy with gemcitabine plus paclitaxel compared with paclitaxel alone for the treatment of women with metastatic breast ...

A slow drug-release system has proven highly effective in treating certain bladder cancer patients whose tumors were previously unresponsive to therapy. A new targeted drug delivery system known as TA ...

Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders ...

Park says patient-specific factors that influence his treatment selection include the presence of liver disease, ...

A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...

The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...